4/A: Revolution Medicines Director Corrects Stock and Option Award Amounts in Amended SEC Filing

Flavia Borellini, a director at Revolution Medicines, filed an amended Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.

Summary

• Flavia Borellini, a director at Revolution Medicines, filed an amendment to a previous Form 4 filing.
• The amendment corrects the amounts reported for restricted stock units (RSUs) and stock options granted to Borellini on June 20, 2024.
• The original Form 4, filed on June 24, 2024, inadvertently reported incorrect amounts.
• The corrected filing shows that Borellini acquired 4,248 shares of common stock through RSUs and 15,955 shares through stock options on June 20, 2024.
• The stock options have an exercise price of $37.54 and vest on the earlier of the first anniversary of the grant date or immediately prior to the company's annual meeting following the grant date, contingent on continued service.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't indicate any fundamental issues with the company, but the initial error suggests a need for improved internal controls. The sentiment is neutral to slightly positive as it shows transparency in correcting the mistake.

Industry Context

Form 4 filings are standard practice for company insiders (directors, officers, and 10% owners) to report transactions in their company's securities to the SEC, ensuring transparency and preventing insider trading. Amendments are filed when errors are discovered in the original filings.

Stakeholder Impact

• The correction of the filing ensures accurate information is available to shareholders and the public.

Key Dates